Ovation Launches the Career of Jeff Aronin

The career of Jeff Aronin has taken him down a number of different paths from his early days as a physician to his current position as one of the leading developers of medical and healthcare startups in the world. Currently, Jeff Aronin is the president and CEO of Paragon Biosciences which has become one of the leading partners for many different startups who look to secure their role in the healthcare industry using the skills and contacts of this impressive brand.


Jeff Aronin has spent much of his career carving out his own position within the global healthcare industry with his first company, Ovation Pharmaceuticals becoming a leading member of the medical industry in just nine short years after being established in 2000. Aronin was inspired to assist those fighting rare medical conditions and those conditions often overlooked by major pharmaceutical companies which ensured the success of the company; by the time the Danish healthcare giant, Lundbeck purchased the brand for $900 million, Jeff Aronin had achieved many of his aims in helping those often ignored in the industry.


After moving to Paragon Biosciences, Jeff Aronin has continued to find success in different areas of his life and career with the company already being awarded 13 drug approvals from the FDA over the course of the last decade; the success rate of the FDA approvals is largely unheard of for a relatively small pharmaceutical and biosciences group and rivals the work being completed by much larger organizations.


Through his work with Paragon Biosciences, Jeff Aronin has been taking a different approach to the success being achieved within the healthcare and medical research fields. At Paragon, Jeff Aronin focuses his work and resources on the development of a range of different options including financing existing companies and startups which are looking to make an impact in the medical sector; the success already achieved has been completed by providing a link between financial experts and the researchers spending their time looking for new ways of securing the medical breakthroughs sought by the most vulnerable within the global community.